BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu XN, Chen H, Liu TT, Wu J, Zhu JM, Shen XZ. Targeting the mTOR regulatory network in hepatocellular carcinoma: Are we making headway? Biochim Biophys Acta Rev Cancer 2019;1871:379-91. [PMID: 30951815 DOI: 10.1016/j.bbcan.2019.03.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu X, Guo H, Liu T, Zhang G, Zhu H, Shi X, Song G, Jiang X, Huang X, Weng S, Dong L, Shen X, Huang Y, Zhu J. Upregulated calcium‐binding tyrosine phosphorylation‐regulated protein‐a/b regulates cell proliferation and apoptosis and predicts poor prognosis in hepatocellular carcinoma. J Cell Biochem 2020;121:2938-49. [DOI: 10.1002/jcb.29538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
2 Geng N, Jin Y, Li Y, Zhu S, Bai H. AKR1B10 Inhibitor Epalrestat Facilitates Sorafenib-Induced Apoptosis and Autophagy Via Targeting the mTOR Pathway in Hepatocellular Carcinoma. Int J Med Sci 2020;17:1246-56. [PMID: 32547320 DOI: 10.7150/ijms.42956] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Zhang E, Chen S, Tang H, Fei C, Yuan Z, Mu X, Qin Y, Liu H, Fan Y, Tan M, Wang X. CDK1/FBXW7 facilitates degradation and ubiquitination of MLST8 to inhibit progression of renal cell carcinoma. Cancer Sci 2021. [PMID: 34741373 DOI: 10.1111/cas.15188] [Reference Citation Analysis]
4 Li X, Xie L, Qu X, Zhao B, Fu W, Wu B, Wu J. GPR91, a critical signaling mechanism in modulating pathophysiologic processes in chronic illnesses. FASEB J 2020;34:13091-105. [PMID: 32812686 DOI: 10.1096/fj.202001037R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
5 Chen H. Nutrient mTORC1 signaling contributes to hepatic lipid metabolism in the pathogenesis of non-alcoholic fatty liver disease. Liver Research 2020;4:15-22. [DOI: 10.1016/j.livres.2020.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Shi Z, Liu R, Lu Q, Zeng Z, Liu Y, Zhao J, Liu X, Li L, Huang H, Yao Y, Huang D, Xu Q. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway. Int J Med Sci 2021;18:3749-58. [PMID: 34790050 DOI: 10.7150/ijms.63220] [Reference Citation Analysis]
7 Lou G, Chen L, Xia C, Wang W, Qi J, Li A, Zhao L, Chen Z, Zheng M, Liu Y. MiR-199a-modified exosomes from adipose tissue-derived mesenchymal stem cells improve hepatocellular carcinoma chemosensitivity through mTOR pathway. J Exp Clin Cancer Res. 2020;39:4. [PMID: 31898515 DOI: 10.1186/s13046-019-1512-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 18.0] [Reference Citation Analysis]
8 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Yang JR, Ling XL, Guan QL. RAP2A promotes apoptosis resistance of hepatocellular carcinoma cells via the mTOR pathway. Clin Exp Med 2021. [PMID: 34018090 DOI: 10.1007/s10238-021-00723-x] [Reference Citation Analysis]
10 Yu XN, Deng Y, Zhang GC, Liu J, Liu TT, Dong L, Zhu CF, Shen XZ, Li YH, Zhu JM. Sorafenib-Conjugated Zinc Phthalocyanine Based Nanocapsule for Trimodal Therapy in an Orthotopic Hepatocellular Carcinoma Xenograft Mouse Model. ACS Appl Mater Interfaces 2020;12:17193-206. [PMID: 32207914 DOI: 10.1021/acsami.0c00375] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Ferrín G, Guerrero M, Amado V, Rodríguez-Perálvarez M, De la Mata M. Activation of mTOR Signaling Pathway in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E1266. [PMID: 32070029 DOI: 10.3390/ijms21041266] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
12 Wu D, Zhang G, Ma J, Wu H, Xiong J, Huang X, Tian Y, Deng T, Han X, Sun X, Xiang T, Yu X, Jiang X. Upregulation of Nei-Like DNA Glycosylase 3 Predicts Poor Prognosis in Hepatocellular Carcinoma. J Oncol 2021;2021:1301671. [PMID: 34659404 DOI: 10.1155/2021/1301671] [Reference Citation Analysis]
13 Liu X, Hu J, Song X, Utpatel K, Zhang Y, Wang P, Lu X, Zhang J, Xu M, Su T, Che L, Wang J, Evert M, Calvisi DF, Chen X. Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E930. [PMID: 31277283 DOI: 10.3390/cancers11070930] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
14 Enkhnaran B, Zhang GC, Zhang NP, Liu HN, Wu H, Xuan S, Yu XN, Song GQ, Shen XZ, Zhu JM, Liu XP, Liu TT. microRNA-106b-5p Promotes Cell Growth and Sensitizes Chemosensitivity to Sorafenib by Targeting the BTG3/Bcl-xL/p27 Signaling Pathway in Hepatocellular Carcinoma. J Oncol 2022;2022:1971559. [PMID: 35342408 DOI: 10.1155/2022/1971559] [Reference Citation Analysis]
15 Bao X, Liu Y, Huang J, Yin S, Sheng H, Han X, Chen Q, Wang T, Chen S, Qiu Y, Zhang C, Yu H. Stachydrine hydrochloride inhibits hepatocellular carcinoma progression via LIF/AMPK axis. Phytomedicine 2022;100:154066. [PMID: 35366490 DOI: 10.1016/j.phymed.2022.154066] [Reference Citation Analysis]
16 Liu C, Yang S, Wang K, Bao X, Liu Y, Zhou S, Liu H, Qiu Y, Wang T, Yu H. Alkaloids from Traditional Chinese Medicine against hepatocellular carcinoma. Biomed Pharmacother 2019;120:109543. [PMID: 31655311 DOI: 10.1016/j.biopha.2019.109543] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]